| INNOCARE-PHARMA-INC |
INNOCARE-PHARMA-INC |
85%
|
ar or identical to ours, and our ability to successfully develop and commercialize our product candidates may be adversely impacted; ● We have relied and expect to continue to rely on third parties… |
| ZAI-LAB-HONG-KONG-LIMITED |
ZAI-LAB-HONG-KONG-LIMITED |
85%
|
the Company granted Zai an exclusive sublicense to develop, manufacture and commercialize ZB001 and related programs in greater China |
| AZN |
AstraZeneca PLC |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| AZN |
AstraZeneca PLC |
72%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are… |
| BHC |
Bausch Health Companies Inc. |
72%
|
Reciprocal relationship from BHC graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are… |
| BHC |
Bausch Health Companies Inc. |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or E… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| CELG-RI |
CELG-RI |
72%
|
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from ZBIO graph: embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates… |
| CELG-RI |
CELG-RI |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| DNTH |
Dianthus Therapeutics, Inc. |
72%
|
Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States an… |
| GSK |
GSK plc |
72%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from GSK graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from GSK grap… |
| GSK |
GSK plc |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| LLY |
Eli Lilly and Company |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from LLY grap… |
| NUVB |
Nuvation Bio Inc. |
72%
|
IL-17AA homodimer and IL-17AF heterodimer signaling. We expect Phase 1 clinical study initiation in 2026. ZB022 is an oral, brain-penetrant tyrosine kinase 2 (“TYK2”)-JH2 inhibitor, currently in Inve… |
| NUVB |
Nuvation Bio Inc. |
72%
|
Reciprocal relationship from NUVB graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NUVB graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NUVB g… |
| NVSEF |
Novartis AG |
72%
|
embly facilities in the U.S. or EU for the global supply. While the drug substances used in our product candidates are manufactured by more than one supplier, we rely on a single third-party manufact… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from NVSE… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZBIO graph: also engage in cyber-attacks for geopolitical reasons and in conjunction with military conflicts and defense activit… |
| SNYNF |
Sanofi |
72%
|
also engage in cyber-attacks for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon w… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from TKPH… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
nt in the US, including the following Phase 3 programs: zasocitinib, a peripheral acting TYK2 inhibitor being developed by Takeda Pharmaceutical Company Limited, envudeucitinib, a brain-penetrant TYK… |
| VRDN |
Viridian Therapeutics, Inc. |
72%
|
IL-17AA homodimer and IL-17AF heterodimer signaling. We expect Phase 1 clinical study initiation in 2026. ZB022 is an oral, brain-penetrant tyrosine kinase 2 (“TYK2”)-JH2 inhibitor, currently in Inve… |
| VRDN |
Viridian Therapeutics, Inc. |
72%
|
Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from VRDN g… |
| BHVN |
Biohaven Ltd. |
62%
|
Reciprocal relationship from BHVN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHVN graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from BHVN g… |
| BIOHAVEN-THERAPEUTICS-LTD |
BIOHAVEN-THERAPEUTICS-LTD |
62%
|
nt in the US, including the following Phase 3 programs: zasocitinib, a peripheral acting TYK2 inhibitor being developed by Takeda Pharmaceutical Company Limited, envudeucitinib, a brain-penetrant TYK… |
| BPCR-LIMITED |
BPCR-LIMITED |
62%
|
g, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all; 152 Table of Contents ● our ability to achieve sufficient market acceptance, coverage and … |
